Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
ALL enters its October 28 earnings date with the Street uniformly trimming price targets and the stock down 14% over the past month, creating a clear tension between a still-positive consensus and a rapidly narrowing margin for disappointment.
The analyst picture is the most telling signal this week. Four bellwether firms cut their targets in the space of six days. Morgan Stanley lowered its target from $265 to $240 on October 6, keeping an Equal-Weight rating. Goldman Sachs moved to $250 from $280 on October 1. Citigroup, which already carries a Sell, cut from $240 to $215 on October 2. Barclays, also Underweight, trimmed to $221 from $226 on October 7. The pattern is consistent: no firm is capitulating on its rating, but every firm is marking down where they think the stock should trade. The mean price target across the analyst panel now stands at $271.50, implying about 21% upside from the $224.27 close, yet that gap has been narrowing quickly and the direction of travel is one-way.
The bull case centres on Allstate's auto underwriting recovery. Policy count is growing, the combined ratio has improved sequentially, and the EPS surprise factor score ranks in the 91st percentile, meaning the company has a strong recent track record of beating estimates. The ORTEX EV/EBIT multiple of approximately 4.6x is near the low end for the sector, and the dividend score ranks in the 96th percentile. Bears point the other way: a year-to-date combined ratio of 89.4% is worse than the company's own 95% long-run target, personal lines pricing is under competitive pressure, and the EPS forward momentum score has collapsed to the 5th percentile over the past 30 days. That last figure matters: it means forward earnings estimates are being cut faster than almost any stock in the coverage universe, and that is almost certainly what is driving the coordinated target reductions.
Positioning in the borrow market tells a very different story from the analyst caution. Short interest is a modest 2.1% of free float, down about 3% on the week, and the lending pool is exceptionally easy to access. Availability has moved back above 8,400%, meaning shares available to borrow dwarf the existing short position by a factor of more than 80. Cost to borrow has fallen 26% on the week to just 0.26%, the lowest level in the 30-day window and near historically negligible levels for a large-cap insurer. There is no sign of short sellers building a meaningful position despite the month's selloff; the stock's ORTEX short score sits at 32.7, near the lower end of its recent range. Options positioning has shifted, though. The put/call ratio at 1.18 is now almost 1.5 standard deviations below its 20-day average of 1.37, which means the options market has actually become less defensive relative to its own recent norm, even as the stock drops. That combination, cheap borrow, falling short interest, easing put demand, suggests the month's price weakness reflects fundamental concern rather than speculative pressure.
Retail attention is also picking up. The ORTEX Wikipedia views signal has a z-score of 1.94 against the stock's own 90-day history, its highest recent reading, indicating above-average interest from ordinary investors in a name that typically sits below the retail radar.
Institutional ownership gives little away. BlackRock reported a 9.0% stake as of September 30, adding about 971,000 shares in the period. State Street and Geode also added modestly. T. Rowe Price, by contrast, has been reducing its position from 5.9% to 4.9% of class over the past year, though that disclosure is from last November and the current position could differ. The insider picture for the past 90 days shows net selling of approximately $23.8 million, though the recent October 3 activity was entirely option exercises and tax-withholding share surrenders, mechanical transactions rather than discretionary sales.
With the Q3 print due October 28, the question the market will be asking is whether the 30-day estimate revision trend that has prompted simultaneous target cuts from four major firms reflects already-known catastrophe-loss data or something more structural about Allstate's pricing and cost trajectory.
See the live data behind this article on ORTEX.
Open ALL on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
